thioacetazone has been researched along with Mycobacterium-avium-intracellulare-Infection* in 2 studies
2 other study(ies) available for thioacetazone and Mycobacterium-avium-intracellulare-Infection
| Article | Year |
|---|---|
SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.
Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone. Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; Liver; Mefloquine; Mice; Mice, Inbred C57BL; Moxifloxacin; Mycobacterium avium-intracellulare Infection; Quinolines; Spleen; Thioacetazone | 2004 |
Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.
In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 micro g/ml or lower. In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens. A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen. Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Fluoroquinolones; Humans; Liver; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines; Spleen; Thioacetazone | 2003 |